mGluR2 Activator

JNJ-46356479 is a blood-brain barrier-penetrant mGluR2/3 allosteric activator. JNJ-46356479 binds to the mGluR2 PAM site to enhance mGluR2 activity, thereby inhibiting presynaptic glutamate release and modulating adenylate cyclase (Adenylate Cyclase), calcium channel (CRAC Channel) activity, and neuronal excitability. JNJ-46356479 exhibits anticonvulsant activity in psychomotor seizures and corneal kindling, and can be used in the study of schizophrenia and epilepsy.

Fasoracetam (NS105) is an orally active metabotropic glutamate receptor (mGluR) activator. Fasoracetam bidirectionally regulates adenylyl cyclase activity and cAMP levels by activating group I-III mGluRs, upregulating GABAB receptors, and enhancing cholinergic neurotransmission. Fasoracetam can be used in research on attention deficit hyperactivity disorder (ADHD), depression, dementia, Alzheimer's disease, and forebrain ischemia.

Quisqualic acid (L-Quisqualic acid), a natural analog of glutamate, is a potent and pan two subsets (iGluR and mGluR) of excitatory amino acid (EAA) agonist with an EC₅₀ of 45 nM and a K_i of 10 nM for mGluR1R. Quisqualic acid is isolated from the fruits of Quisqualis indica.

Talaglumetad (LY-544344) is an orally active prodrug of Eglumegad (HY-18941) and a metabotropic glutamate receptor 2/3 (mGluR2/3) agonist. Talaglumetad undergoes transmembrane transport via the intestinal peptide transporter hPepT1, and is enzymatically hydrolyzed to produce L-alanine and the parent drug Eglumegad after entering the body. Talaglumetad can be used in research related to metabotropic glutamate receptor 2-associated neurological systems.

Fasoracetam (NS 105) Standard is the analytical standard of Fasoracetam (HY-107481). This product is intended for research and analytical applications. Fasoracetam (NS105) is an orally active metabotropic glutamate receptor (mGluR) activator. Fasoracetam bidirectionally regulates adenylyl cyclase activity and cAMP levels by activating group I-III mGluRs, upregulating GABAB receptors, and enhancing cholinergic neurotransmission. Fasoracetam can be used in research on attention deficit hyperactivity disorder (ADHD), depression, dementia, Alzheimer's disease, and forebrain ischemia.